E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 meredith.weissman@zimmerbiomet.com keri.mattox@zimmerbiomet.com Heather Zoumas-Lubeski (445) 2

Zimmer Biomet Announces Leadership Transition

Chief Operating Officer Ivan Tornos Appointed President and CEO;

Elected to the Board of Directors

Chief Financial Officer Suketu (Suky) Upadhyay s Role Expands to

CFO and EVP, Finance, Operations & Supply Chain

Company Reaffirms Full-Year 2023 Financial Guidance

(WARSAW, IN) August 22, 2023 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced the appointment of Ivan Tornos as

President and Chief Executive Officer (CEO) and election to the Board of Directors, effective immediately. Mr. Tornos has most recently served as Chief Operating Officer of Zimmer Biomet, a role he has held since early 2021. He takes over as

President and CEO from Bryan Hanson, who has served as the Company s President and CEO since late 2017 and Chairman since 2021, and is departing to take on another CEO role.

Suketu (Suky) Upadhyay, who joined Zimmer Biomet in 2019 as Executive Vice President (EVP) and Chief

Financial Officer (CFO), is expanding his role to also include full responsibility for overseeing the Company s global Operations and Supply Chain functions. Additionally, current Lead Independent Director Christopher Begley takes on the role

of Chairman of the Board, effective today.

The Company is reaffirming its full-year 2023 financial guidance as outlined in the second quarter

financial results announced on August 1, 2023.

It is an honor to be appointed CEO of Zimmer Biomet at a time when our execution is

extremely strong and our innovation momentum is at an all-time high, said Mr. Tornos. I am grateful for Bryan s leadership in transforming the Company and am now looking forward to

leading the team and accelerating our ZB strategy to drive continued growth and boldly advance the standard of musculoskeletal care.

Mr. Tornos joined Zimmer Biomet in November 2018 as Group President, Orthopedics and a year later was named Group President, Global

Businesses and the Americas. He was appointed Chief Operating Officer in March 2021 with responsibility for overseeing all global businesses at Zimmer Biomet, as well as leading the global operations, clinical and medical education and global

R&D and New Product Development functions. In this role, he had oversight of the Americas and the Europe, Middle East and Africa (EMEA) regions.

Prior to joining Zimmer Biomet, Mr. Tornos served as Worldwide President of the Global Urology, Medical and Critical Care Division of Becton, Dickinson

and Company. Earlier, he was with C.R. Bard in positions of increasing responsibility, most recently serving as President, EMEA. Before joining C.R. Bard, Mr. Tornos served as Vice President and General Manager of the Americas Pharmaceutical

and Medical/Imaging segments of Covidien International. He also served as

International Vice President, Business Development and Strategy with Baxter International Inc., and prior to that he spent over a decade in leadership assignments around the globe with

Johnson & Johnson. Mr. Tornos currently serves as an independent member of the Board of Directors of global healthcare company PHC Holdings Corporation.

Ivan has consistently delivered strong results since joining Zimmer Biomet. His deep expertise in the medtech sector, commercial prowess and proven

leadership experience make him the ideal leader for Zimmer Biomet as we move into our next phase of innovation and growth, said Mr. Begley. As a Board of Directors, we are extremely pleased with the strength of the Company s

succession planning efforts, the depth of the management team and Ivan s appointment. On behalf of the entire Board, I thank Bryan for his tremendous service to the organization and his role in establishing the Company as a leading player in

Today it was announced that Mr. Hanson will be assuming the role of CEO of the healthcare spinoff of 3M. During his tenure

at Zimmer Biomet, he spearheaded the Company s transformation, reshaping the mission, culture, corporate strategy, quality, compliance, operations and market performance. Mr. Hanson also successfully orchestrated the spinoff of the

Company s Spine and Dental franchises to an independent company, ZimVie Inc.

The last five and a half years at the helm of Zimmer Biomet have

been transformational, not just for the Company, but for me, as well, said Mr. Hanson. I have the utmost confidence in Ivan, the entire ZB team and the strength of the business. I cannot think of a better leader to continue to move

the ZB mission forward and deliver value for patients, customers and shareholders.

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We

seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and

providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our

product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of

1995. Forward-looking statements may be identified by the use of forward-looking terms such as may, will, expects, believes, aims, anticipates, plans, looking

forward to, estimates, projects, assumes, guides, targets, forecasts, continue, seeks or the negatives of such terms or other variations on such

terms or comparable terminology. Forward-looking statements include, but are not limited to, statements concerning the Company s financial guidance, forecasts, expectations, plans, intentions, strategies, prospects, business plans and other

statements that are not historical facts. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially.

and uncertainties can be found in Zimmer Biomet s Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent

periodic reports filed with the Securities and Exchange Commission (SEC). Copies of these filings are available online at www.sec.gov, www.zimmerbiomet.com or on request from the Company. These factors should not be construed as

exhaustive and should be read in conjunction with the other cautionary statements that are included in the Company s filings with the SEC. Such forward-looking statements speak only as of the date made, and the Company disclaims any

intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this press release are cautioned not to place undue reliance on these forward-looking

statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this press release.